Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Changing home designs and materials to make homes cooler and harder for mosquitoes to enter could reduce malaria transmission in sub-Saharan Africa, according to a new study in The Lancet Planetary Health.

African homes

Study researchers found 96% fewer mosquitoes in a Southeast Asian style two storey house built with permeable local bamboo walls and screened windows compared to a traditional mud or wattle-daub African home built on the ground with poor ventilation.

“New house designs could become an important health intervention in the fight against malaria in Africa,” said Dr Lorenz von Seidlein, study author and Head of Targeted Malaria Elimination at the Mahidol-Oxford Tropical Medicine Research Unit (MORU) in Bangkok, Thailand.

“Between 80-100% of malaria transmission there occurs indoors at night, yet people often don’t sleep under insecticide-treated bednets because they are uncomfortably hot. We think there is an unprecedented opportunity to fight malaria transmission in hot, humid Sub-Saharan Africa by designing homes that keep the cool in and mosquitoes out,” said Dr von Seidlein.

Funded by the Ruth W Jensens Foundation, Denmark, and the Hanako Foundation, Singapore, the study built six prototype houses based on a Southeast Asian design in the village of Magoda in Muheza District, Tanga Region, Tanzania, and compared them with modified and unmodified traditional, sub-Saharan African houses.

The prototype houses were designed by Prof Jakob Knudsen of the University of Copenhagen School of Architecture (KADK) and owner of Ingvartsen, a practice in Copenhagen. In June 2015, long-time Shoklo Malaria Research Unit (SMRU) staff member Mr. Tip Ruechaitrakul, two Karen colleagues and a local Tanzanian craftsman built a typical two storey Thai-Karen house that was included the study and found to have the best climate comfort index of all study houses.

Researchers found that while both Southeast Asia style single and two storey buildings provided a cooler indoor climate than traditional housing, two-storey buildings provided the biggest reduction in mosquito densities, with 96% fewer mosquitoes than in a traditional African home.

“Our next step is a randomised trial to prove (or disprove) whether the findings hold in a substantial number of African houses and villages. We are looking for funding for a household randomised cohort trial where 110 households receive a novel design home and are compared with a cohort of residents living in 440 traditional, rural African homes,” said Dr von Seidlein.

Study reference (an error-free, updated version should be available 4 Sept 2017)

Affordable house designs to improve health in rural Africa: a field study in northeastern Tanzania. von Seidlein L, Ikonomidis K, Mshamu S, Nkya TE, Mukaka M, Pell C, Lindsay SW, Deen JL, Kisinza WN, Knudsen JB. The Lancet Planetary Health, vol 1, No. 5, e188-e199, Aug 2017. DOI: http://dx.doi.org/10.1016/S2542-5196(17)30078-5. http://www.thelancet.com/journals/lanplh/article/PIIS2542-5196(17)30078-5/fulltext

Similar stories

The RECOVERY Trial: One year on

OCGHR Research

The Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial was officially launched on 23 March 2020. It is the world's largest COVID-19 drug trial. Thanks to the ground-breaking work of RECOVERY, clinicians treating patients hospitalised with severe COVID-19 now have two treatments that are known to improve survival.

Researchers call for access to Ivermectin for young children

OCGHR Publication Research

Millions of children weighing less than 15kg are currently denied access to Ivermectin treatment due to insufficient safety data being available to support a change to the current label indication. The WorldWide Antimalarial Resistance Network’s new meta-analysis provides evidence that supports removing this barrier and improving treatment equity.

Gender imbalance in visceral leishmaniasis clinical trials

OCGHR Publication Research

Researchers have found that despite an ongoing trend for a decreasing proportion of males being enrolled in antileishmanial therapeutic efficacy trials over time, there are still 1.8 times as many males as females involved in clinical trials. A new systematic review and meta-analysis suggests that existing knowledge on drug efficacy is derived from a study population that is heavily skewed towards adult males. At the same time, substantially less is known about the optimal treatment response in female patients.

New report highlights growing concern of vaccine falsification

MORU OCGHR

The Medicine Quality Research Group has published a new Medical Product Quality Report focussing on increasing issues around substandard and falsified (SF) COVID-19 vaccines. With the implementation of the key innovations of COVID-19 vaccines, there have been growing numbers of reports of SF vaccines in the public domain. Given the vital role they will play in ending the pandemic and protecting the global population but severe issues with equitable access, SF vaccines are highly likely to be a growing problem.

RECOVERY trial closes recruitment to colchicine treatment for patients hospitalised with COVID-19

OCGHR Research

Established to test a range of potential treatments for COVID-19, the RECOVERY trial has included a comparison of colchicine, an anti-inflammatory drug that is commonly used to treat gout, vs. usual care alone. There has been no convincing evidence of the effect of colchicine on clinical outcomes in patients admitted to hospital with COVID-19, and recruitment to the colchicine arm of the RECOVERY trial has now closed. Recruitment to all other treatment arms – aspirin, baricitinib, Regeneron’s antibody cocktail, and dimethyl fumarate – continues as planned.

World’s largest clinical trial for COVID-19 treatments expands internationally

EOCRU OCGHR OUCRU OUCRU-Nepal Research

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.